HRP20181672T1 - Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma - Google Patents
Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinomaInfo
- Publication number
- HRP20181672T1 HRP20181672T1 HRP20181672TT HRP20181672T HRP20181672T1 HR P20181672 T1 HRP20181672 T1 HR P20181672T1 HR P20181672T T HRP20181672T T HR P20181672TT HR P20181672 T HRP20181672 T HR P20181672T HR P20181672 T1 HRP20181672 T1 HR P20181672T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancers
- hetero
- treatment
- aromatic compounds
- compounds useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416186.3A GB201416186D0 (en) | 2014-09-12 | 2014-09-12 | Compounds |
| PCT/GB2015/052640 WO2016038389A1 (en) | 2014-09-12 | 2015-09-11 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers |
| EP15766218.0A EP3191477B1 (en) | 2014-09-12 | 2015-09-11 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20181672T1 true HRP20181672T1 (hr) | 2019-02-08 |
Family
ID=51869542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181672TT HRP20181672T1 (hr) | 2014-09-12 | 2018-10-15 | Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | USRE49361E1 (hr) |
| EP (1) | EP3191477B1 (hr) |
| JP (1) | JP6781150B2 (hr) |
| CN (1) | CN107108588B (hr) |
| AU (1) | AU2015314007B2 (hr) |
| CA (1) | CA2960477C (hr) |
| DK (1) | DK3191477T3 (hr) |
| ES (1) | ES2702477T3 (hr) |
| GB (1) | GB201416186D0 (hr) |
| HR (1) | HRP20181672T1 (hr) |
| HU (1) | HUE041751T2 (hr) |
| WO (1) | WO2016038389A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| MX2023001274A (es) * | 2020-07-28 | 2023-04-24 | Jazz Pharmaceuticals Ireland Ltd | Sintesis quiral de inhibidores de raf biciclicos fusionados. |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698550A (en) * | 1993-06-14 | 1997-12-16 | Pfizer Inc. | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1690056A (zh) | 2004-04-30 | 2005-11-02 | 北京大学 | 三个化合物及其制备方法和用途 |
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| AU2006322094A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| BR112014013108B1 (pt) * | 2011-12-31 | 2020-11-24 | Beigene, Ltd. | compostos, composição farmacêutica, uso do composto e método |
-
2014
- 2014-09-12 GB GBGB1416186.3A patent/GB201416186D0/en not_active Ceased
-
2015
- 2015-09-11 EP EP15766218.0A patent/EP3191477B1/en active Active
- 2015-09-11 DK DK15766218.0T patent/DK3191477T3/en active
- 2015-09-11 AU AU2015314007A patent/AU2015314007B2/en active Active
- 2015-09-11 US US17/102,621 patent/USRE49361E1/en active Active
- 2015-09-11 CN CN201580061422.2A patent/CN107108588B/zh active Active
- 2015-09-11 ES ES15766218T patent/ES2702477T3/es active Active
- 2015-09-11 WO PCT/GB2015/052640 patent/WO2016038389A1/en active Application Filing
- 2015-09-11 CA CA2960477A patent/CA2960477C/en active Active
- 2015-09-11 HU HUE15766218A patent/HUE041751T2/hu unknown
- 2015-09-11 JP JP2017513631A patent/JP6781150B2/ja active Active
- 2015-09-11 US US15/509,952 patent/US10183939B2/en not_active Ceased
-
2018
- 2018-10-15 HR HRP20181672TT patent/HRP20181672T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2960477A1 (en) | 2016-03-17 |
| JP2017527586A (ja) | 2017-09-21 |
| WO2016038389A1 (en) | 2016-03-17 |
| USRE49361E1 (en) | 2023-01-10 |
| JP6781150B2 (ja) | 2020-11-04 |
| DK3191477T3 (en) | 2018-11-05 |
| GB201416186D0 (en) | 2014-10-29 |
| AU2015314007B2 (en) | 2020-03-05 |
| US20170298061A1 (en) | 2017-10-19 |
| ES2702477T3 (es) | 2019-03-01 |
| HUE041751T2 (hu) | 2019-05-28 |
| US10183939B2 (en) | 2019-01-22 |
| CN107108588A (zh) | 2017-08-29 |
| CA2960477C (en) | 2023-02-14 |
| EP3191477B1 (en) | 2018-07-18 |
| EP3191477A1 (en) | 2017-07-19 |
| CN107108588B (zh) | 2021-06-01 |
| AU2015314007A1 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244802A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
| IL261551B (en) | bicyclic compounds | |
| HRP20181672T1 (hr) | Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma | |
| HK1245795A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
| ZA201701210B (en) | Substituted bicyclic compounds | |
| HRP20190121T1 (hr) | Novi kondenzirani imidazo benzothiazole spojevi | |
| HK1249756A1 (zh) | 用於治療疾病的稠合雙環化合物 | |
| HK1252614A1 (zh) | 二環化合物 | |
| IL263177A (en) | Fused bicyclic compounds for the treatment of disease | |
| ZA201606921B (en) | Use of xanthophylls for the treatment of cancers | |
| IL262448B (en) | Disubstituted heterocyclic bicyclic compounds | |
| ZA201701099B (en) | Process for the preparation of aromatic compounds | |
| IL270966A (en) | Fused bicyclic compounds | |
| ZA201704589B (en) | Compounds for the treatment of cancer |